Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by theo12on Aug 13, 2018 6:32pm
197 Views
Post# 28453180

RE:Still not convinced?

RE:Still not convinced?20 years ago,  Th was VERY promising.  And its history has been up and down with the promising egrifta,  and was down when luck happenned with trogarzo.
Approval came up in Marh 2018.  Then its PS, already high with expectation, boomed.
And now its PS is failing.  With reason. Despite the good news, where are the results. No news on sales, and if some, which is egrifta, which is trogarzo? Is there an evolution, a trend? Is there something to say (where are the analists)? The name of the game is figures.  Where are they? Whithout news on evolution on sales, how could the PS stayed at 13-14 $.after approval? Th has to show positive results before its resurrection. 
That being said, I think the actual valus is fair. As for the furure, we might see in October.  If negative or so, the PS might go down to I guess approximately 3$.  But if the figures are positive and promising, with an explained evolution plan that will be possible to follow (rather than '' it goes as planned''), then I see the PS in October at 15-16 $,  and maybe 25$ by Christmass, and then start to dream as a result of the latest good news.
So  lets hope for good results.


Bullboard Posts